이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Bicycle Therapeutics 관리
관리 기준 확인 4/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Kevin Lee
최고 경영자
US$5.5m
총 보상
| CEO 급여 비율 | 12.8% |
| CEO 임기 | 9yrs |
| CEO 소유권 | 0.4% |
| 경영진 평균 재임 기간 | 3.5yrs |
| 이사회 평균 재임 기간 | 5.2yrs |
최근 관리 업데이트
Recent updates
Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10
Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$165m |
| Mar 31 2024 | n/a | n/a | -US$168m |
| Dec 31 2023 | US$6m | US$710k | -US$181m |
| Sep 30 2023 | n/a | n/a | -US$162m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$124m |
| Dec 31 2022 | US$9m | US$673k | -US$113m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$87m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$677k | -US$67m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$62m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$3m | US$592k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$37m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$4m | US$517k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$33m |
| Jun 30 2019 | n/a | n/a | -US$31m |
| Mar 31 2019 | n/a | n/a | -US$26m |
| Dec 31 2018 | US$818k | US$386k | -US$22m |
보상 대 시장: Kevin 의 총 보상 ($USD 5.54M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 5.67M ).
보상과 수익: Kevin 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Kevin Lee (56 yo)
9yrs
테뉴어
US$5,540,400
보상
Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Executive Director | 9yrs | US$5.54m | 0.37% $ 5.9m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.8m | |
| Chief Financial Officer | 1.2yrs | US$2.88m | 데이터 없음 | |
| Chief Development Officer | 1.5yrs | US$2.82m | 0% $ 0 | |
| Scientific Founder | no data | 데이터 없음 | 데이터 없음 | |
| Chief Operating Officer | 2.7yrs | US$5.98m | 0.023% $ 364.6k | |
| Senior VP | 1.3yrs | 데이터 없음 | 0.0033% $ 52.5k | |
| Chief Technology Officer | 2.7yrs | US$3.07m | 0.072% $ 1.1m | |
| General Counsel | 4.4yrs | 데이터 없음 | 데이터 없음 | |
| Head of Clinical and Project Management | 8.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP of Pre-Clinical Development | 5.8yrs | 데이터 없음 | 데이터 없음 | |
| Chief Business Officer | 5yrs | US$1.40m | 0.012% $ 191.0k |
3.5yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 관리: BCYC 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Executive Director | 9yrs | US$5.54m | 0.37% $ 5.9m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.8m | |
| Chairman of Scientific Advisory Board | 6.3yrs | 데이터 없음 | 데이터 없음 | |
| Non-Executive Chairman | 5.5yrs | US$1.06m | 0.031% $ 499.0k | |
| Independent Non-Executive Director | 3.5yrs | US$482.29k | 0.016% $ 249.5k | |
| Independent Non-Executive Director | 5.2yrs | US$526.91k | 0.016% $ 249.5k | |
| Member of Scientific Advisory Board | 3.9yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.9yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 5.2yrs | US$495.41k | 0.016% $ 249.5k | |
| Member of Scientific Advisory Board | 6.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.9yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.9yrs | 데이터 없음 | 데이터 없음 |
5.2yrs
평균 재임 기간
64yo
평균 연령
경험이 풍부한 이사회: BCYC 의 이사회는 경험(평균 재직 기간 4.9 년)으로 간주됩니다.